Injections frequency and health care costs in patients treated with aflibercept compared to ranibizumab: new real-life evidence from Switzerland

BACKGROUND: Previous analyses of real-life data indicated that injection frequency and health care costs did not differ for anti-VEGF treatment with aflibercept and ranibizumab. The objective of this study was to investigate whether this finding persisted when analysing a longer time period after li...

Descripción completa

Detalles Bibliográficos
Autores principales: Reich, Oliver, Schmid, Martin K., Rapold, Roland, Bachmann, Lucas M., Blozik, Eva
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5715627/
https://www.ncbi.nlm.nih.gov/pubmed/29202760
http://dx.doi.org/10.1186/s12886-017-0617-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5715627/
https://www.ncbi.nlm.nih.gov/pubmed/29202760
http://dx.doi.org/10.1186/s12886-017-0617-x

Ejemplares similares